- 2014
- What's on? - 04.02.2014
World cancer day
On World Cancer Day, visit the press room to see the latest press releases and packs on cancer. For further information about cancer (the latest figures and major landmarks), take a look at the WHO site.
- Press releases - 31.01.2014
ERC: France, the leading country for life sciences in Europe
The European Research Council (ERC) has just awarded Consolidator Grants to 19 French projects in life sciences, thereby placing France at the head of European countries submitting proposals in this area.
- News in brief - 29.01.2014
Europe supports stem cell research for the treatment of diabetes
A €6 million grant awarded to the HumEn project by the European Commission has helped bring together the main institutes carrying out stem cell research, including Inserm, and European industrial partners wishing to develop insulin-producing cells as a future cell replacement therapy for diabetes. The complete maturation of human pluripotent stem cells into transplantable beta […]
- Press releases - 23.01.2014
Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy
A team of French researchers, led by Dr. Anna Buj-Bello (Genethon/Inserm) and teams at the University of Washington and Harvard Medical School in the United States, have demonstrated the efficacy of gene therapy in models of myotubular myopathy, an extremely severe neuromuscular disease in children.
- Press releases - 16.01.2014
Inserm is celebrating its 50th anniversary in 2014: first dates for your diary
The French national institute of health and medical research is celebrating its 50th anniversary in 2014. Below you will see a list of the first key events this year.
- Press releases - 16.01.2014
Heavy drinking in adulthood accelerates cognitive decline in men
According to the results of an epidemiological study conducted jointly by French and English researchers at Inserm and University College London, men who drink more than 36 grams of alcohol (3.5 drinks) per day may have a faster decline in memory, which is reflected by a reduction in their attention and reasoning skills.
- Press releases - 15.01.2014
Chlordecone exposure and risk of preterm birth: new finding
Scientists at the Research Institute for Environmental and Occupational Health (Inserm unit 1085) in Rennes and Pointe-à-Pitre – in collaboration with the gynaecology and obstetrics department at the university hospital of Pointe à Pitre/Abymes and the Center for Analytical Research and Technology at the University of Liège – are publishing an article this week on the impact of chlordecone exposure on pregnancy duration and the risk of preterm birth (birth occurring before the 37th week of amenorrhoea).
- Press releases - 14.01.2014
FameLab, competition of scientific communication
Do you want to share your passion for science? FameLab France needs you! FameLab, the international science communication competition, is launching in France for the first time in 2014 in partnership with AMSCTI, Inserm, CNES, CERN and Paris Diderot – Sorbonne Paris Cité University.
- Press releases - 13.01.2014
Leukemia: mode of action of a targeted treatment clarified
The mechanism of senescence – or premature cell ageing – can have an anticancer effect. This new work, conducted by Hugues de Thé and his team (Paris Diderot University/ Inserm/ CNRS/ AP-HP), was published in Nature Medicine on 12 January 2014.
- Press releases - 10.01.2014
Parkinson’s disease: an immense step forward thanks to gene therapy
A French and English team (AP-HP, Inserm, UPEC, CEA/Mircen, Oxford Biomedica, Cambridge University) has conducted a clinical phase 1/2 gene therapy study among patients suffering from an evolved form of Parkinson’s disease. Fifteen patients were able to benefit from this new treatment, which involves injecting a vector expressing the genes of three enzymes that are essential for the biosynthesis of dopamine, which is lacking in Parkinson’s disease. Thanks to this therapy certain cells in the brain begin to produce and secrete dopamine again. In all the patients, the motor symptoms of the disease were improved for up to 12 months after administration of the treatment. After a period of four years, this study is at this stage demonstrating innocuousness and tolerance of the lentiviral vector used for the first time in human beings. This study was coordinated by Prof. Stéphane Palfi, head of neurosurgery at Henri-Mondor Hospital (AP-HP) within the framework of the neurolocomotor research cluster directed by Prof. Césaro.